2020 PRESENTING COMPANIES
October 15th, 2020 at the following time:
1:00PM - 4:30PM Eastern Time
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye. In the United States, Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie is expanding globally, with offices and clinical development activities in Europe and Japan. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% has been approved in the EU and Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% has been filed with the EMA. Aerie is also pursuing additional product candidates in ophthalmology, including a Phase 2 dry eye program, AR-15512 (TRPM8 agonist), and two clinical-stage retina programs, AR-1105 (dexamethasone) Sustained Release Implant and AR-13503 (Rho kinase/Protein kinase C inhibitor) Sustained Release Implant, and exploring the development potential of other assets from its proprietary library of small-molecule multi-kinase inhibitors.
Equinox Ophthalmic, Inc., is a venture backed medical device manufacturer focused on commercializing patient centric medical technologies for people with glaucoma. The company has developed a revolutionary technology that is a programmable, non-invasive, non-surgical, and non-pharmacological way to lower IOP in even the most difficult to treat glaucomas.
Phase 2 Ophthalmology company with a completely unique MOA and advantageous small molecule to provide neuroprotection and to slow progression in dry AMD and glaucoma, licensed from Tel Aviv University and Merz Pharma. The drug has very high affinity/specificity to misfolded amyloid beta, to block formation of toxic oligomers and reduce their toxicity to neural tissues. Eye drop administration reproducibly achieved >90% neuroprotection in glaucoma rat models and compelling efficacy evidence in AMD models, retinal delivery in monkeys, and excellent safety in completed Phase 1 study (n=70). Including the top members of the neuro team at Merz, Galimedix enjoys the support of world leading retinal and glaucoma experts. Raising funds for brief Phase 2 studies to prove concept in dry AMD and in glaucoma.
iSTAR Medical is a clinical-stage company focused on the development of novel ophthalmic implants for glaucoma. It has exclusive rights to a novel porous material called STAR(r) which exhibits outstanding anti-fibrotic properties therefore providing the foundation for the development of a new class of MIGS devices.
Leo Lens Pharma
Leo Lens is an emerging San Diego-based pharmaceutical company focused on helping protect sight by developing and commercializing a proprietary continuous ocular drug delivery portfolio. We are currently advancing our lead asset, a unique and complete glaucoma treatment, to the clinic while continuing to build out our product portfolio for dry eye, allergy, and other anterior segment conditions. Using our proprietary MediPrint™ process, we will initially commercialize a drug-eluting, comfort-enhancing contact lens to treat millions of glaucoma patients worldwide.
Sanoculis is developing and markets the MIMS (Minimally Invasive Micro Sclerostomy) device and technique for the treatment of the Glaucoma.
MIMS is simple, fast, and minimally invasive. During the procedure, a sclero-corneal drainage channel is created to reduce IOP. The novelty of the solution is that the channel ensures long-lasting controlled fluid flow with minor complications. MIMS consists of a disposable sterile tool and a multi-use external machine. Its expected benefits are: a stent-less procedure, low risk of complications, it is suitable for most Glaucoma patients, has the potential for medication reduction, can be easily combined with Cataract surgery and surgeon-friendly, automatic with short learning curve. MIMS is designed to reduce caring costs through procedure simplicity, low cost, fewer post-surgical complications and less hospitalization.
"Smartlens is a clinical-stage company with a vision of preventing blindness due to Glaucoma. Smartlens has developed a non-invasive, electronics-free, ultra-sensitive, soft contact lens that monitors IOP, the primary and only modifiable risk factor of Glaucoma.
Smartlens’ intuitive technology helps improve the understanding of disease progression, and treatment efficacy. It builds the foundation of a better patient engagement and enables better decisions about diagnosis and personalizing the treatment. Our platform provides seamless telehealth and remote patient monitoring capabilities and helps improve clinical workflow, reducing treatment costs and opening a new era in understanding the relationship between IOP, Glaucoma, other diseases and life-style.
Our intuitive technologies enable “on-the-go” IOP measurements anywhere any time, which are shared with the medical provider as actionable insights through their easy-to-use dashboard. With its strong IP, Smartlens has the unique opportunity to help prevent Glaucoma-related blindness and improve management of the disease with frequent IOP measurements."